Quantcast
Last updated on April 19, 2014 at 1:20 EDT

Latest Haemophilia Stories

2013-06-27 08:30:58

Studies will feature research on novel investigational recombinant factor VIIa, VIII and IX therapies for hemophilia A and B KING OF PRUSSIA, Pa., June 27, 2013 /PRNewswire/ -- CSL Behring today announced it will present study data from three ongoing clinical trial programs evaluating the Company's novel recombinant factor VIIa (rVIIa-FP), VIII (rVIII-SingleChain) and IX (rIX-FP) agents for people with hemophilia A and B with and without inhibitors. The data will be presented at the...

2013-06-25 08:29:10

MONTREAL, June 25, 2013 /PRNewswire/ - For 50 years, the World Federation of Hemophilia (WFH) has provided global leadership to improve and sustain care for people with inherited bleeding disorders, including hemophilia, von Willebrand disease, rare factor deficiencies, and inherited platelet disorders. Fifty years ago, on June 25, 1963, the WFH held its first meeting in Copenhagen, Denmark. Working with leaders from a group of national patient associations, Frank Schnabel, WFH...

2013-06-04 08:30:59

Results of Part 1 of the study will be presented at the 2013 International Society on Thrombosis and Haemostasis in Amsterdam, Netherlands on 2 July, 2013 KING OF PRUSSIA, Pa., June 4, 2013 /PRNewswire/ -- CSL Behring has dosed the first patient in Part 3 of its AFFINITY clinical trial program, which is now in phase III. AFFINITY is an open-label, non-randomized, multi-center study evaluating the efficacy, safety and pharmacokinetics of its novel investigational recombinant...

2013-05-13 23:01:35

47-year-old Texan is cycling 3,456 miles from California to Massachusetts to remember lost family and friends and help people suffering with hemophilia in developing countries. Georgetown, MA (PRWEB) May 13, 2013 Cyclist Barry Haarde commenced his second cross-country bike tour, “Wheels for the World 2013: Fast and Furious,” in Costa Mesa, California on April 20 to raise funds for Save One Life. Save One Life supports over 1,000 impoverished children and adults with hemophilia...

2013-04-30 12:27:15

Kcentra(TM) Is the First FDA-Approved 4-Factor Prothrombin Complex Concentrate for Warfarin Reversal in the U.S. KING OF PRUSSIA, Pa., April 30, 2013 /PRNewswire/ -- CSL Behring announced today that the U.S. Food and Drug Administration (FDA) approved Kcentra(TM) (Prothrombin Complex Concentrate [Human]), the first non-activated 4-factor prothrombin complex concentrate (PCC) for the urgent reversal of acquired coagulation factor deficiency induced by vitamin K antagonist (e.g.,...

2013-04-16 12:27:52

MONTREAL, April 16, 2013 /PRNewswire/ -- The global bleeding disorders community will come together on April 17 to mark World Hemophilia Day. This event takes on a special significance as it coincides with the 50(th) anniversary of the World Federation of Hemophilia (WFH). To commemorate its 50(th) anniversary, the WFH has launched a hemophilia awareness video entitled The Journey Begins. It explores the origins of the WFH and the inspired role that Frank Schnabel played in bringing...

2013-04-03 08:27:56

CSL Behring initiates first "installment" of renewed 3-year commitment to WFH to donate coagulation factor to the WFH Global Alliance for Progress program KING OF PRUSSIA, Pa., April 3, 2013 /PRNewswire/ -- As part of its ongoing commitment to the global coagulation disorders community, CSL Behring will again donate factor product to the World Federation of Hemophilia (WFH) in connection with World Hemophilia Day this month. The medicine will be used in treating patients in...

2013-04-02 00:20:35

WebTracker-Hemophilia Software Used as the National Information Infrastructure Given New Brand Name HemaGlobal for Overseas Markets SAN FRANCISCO, April 2, 2013 /PRNewswire/ -- GZS, Inc., a leader in developing disease-specific and condition-specific Electronic Medical Records/Electronic Health Records (EMR/EHR) and patient registry software solutions, has announced the worldwide release of the WebTracker-Hemophilia((TM)) EHR patient registry solution used under the new brand name...

2013-02-28 08:31:17

Label broadened to include the peri-operative management of surgical bleeding in adult and pediatric patients with congenital factor XIII deficiency KING OF PRUSSIA, Pa., Feb. 28, 2013 /PRNewswire/ -- CSL Behring announced today that the U.S. Food and Drug Administration (FDA) has approved an expansion of the indication for Corifact(®), Factor XIII Concentrate (Human), to include the peri-operative management of surgical bleeding in adult and pediatric patients with congenital...

2013-02-06 08:26:39

WARSAW, Poland and NES-ZIONA, Israel, Feb. 6, 2013 /PRNewswire/ -- PROLOR Biotech, Inc. (NYSE MKT: PBTH), today announced that the company will present new data on its long-acting clotting factor VIIa (Factor Vlla-CTP) at the Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD). PROLOR's Factor VIIa-CTP is a next-generation investigational therapy currently in advanced preclinical development for the potential treatment of patients with hemophilia....